IN2014DN03451A - - Google Patents
Info
- Publication number
- IN2014DN03451A IN2014DN03451A IN3451DEN2014A IN2014DN03451A IN 2014DN03451 A IN2014DN03451 A IN 2014DN03451A IN 3451DEN2014 A IN3451DEN2014 A IN 3451DEN2014A IN 2014DN03451 A IN2014DN03451 A IN 2014DN03451A
- Authority
- IN
- India
- Prior art keywords
- seq
- chain variable
- variable domain
- sequence given
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
Abstract
A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4 in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558559P | 2011-11-11 | 2011-11-11 | |
| PCT/EP2012/072335 WO2013068571A1 (en) | 2011-11-11 | 2012-11-09 | Albumin binding antibodies and binding fragments thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN03451A true IN2014DN03451A (en) | 2015-06-05 |
Family
ID=47358092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3451DEN2014 IN2014DN03451A (en) | 2011-11-11 | 2012-11-09 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9803004B2 (en) |
| EP (1) | EP2776466B1 (en) |
| JP (1) | JP6411214B2 (en) |
| KR (1) | KR102048382B1 (en) |
| CN (1) | CN103946237B (en) |
| AU (1) | AU2012335496B2 (en) |
| BR (1) | BR112014011304B1 (en) |
| CA (1) | CA2856216C (en) |
| CY (1) | CY1119647T1 (en) |
| DK (1) | DK2776466T3 (en) |
| EA (1) | EA033766B1 (en) |
| ES (1) | ES2649098T3 (en) |
| HR (1) | HRP20171608T1 (en) |
| HU (1) | HUE037142T2 (en) |
| IL (1) | IL232226B (en) |
| IN (1) | IN2014DN03451A (en) |
| LT (1) | LT2776466T (en) |
| MX (1) | MX351502B (en) |
| NO (1) | NO2839445T3 (en) |
| PL (1) | PL2776466T3 (en) |
| PT (1) | PT2776466T (en) |
| SG (1) | SG11201401649VA (en) |
| SI (1) | SI2776466T1 (en) |
| WO (1) | WO2013068571A1 (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112203C2 (en) * | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| JP6422977B2 (en) * | 2013-08-30 | 2018-11-14 | エイプリルバイオ カンパニー リミテッド | Antiserum albumin FAB effector partial fusion construct and method for producing the same |
| GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| PH12017502013B1 (en) | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| GB201508180D0 (en) * | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| MA41670A1 (en) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Antibodies binding to tau |
| TN2017000543A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| DK3359688T3 (en) | 2015-10-05 | 2021-08-23 | Biogen Ma Inc | MOLECULAR SIGNATURES FOR USE FOR DIAGNOSIS AND ANALYSIS OF RESPONSE TO TREATMENT OF AUTOIMMUNAL DISEASES |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| GB201602938D0 (en) | 2016-02-19 | 2016-04-06 | Ucb Biopharma Sprl | Protein purification |
| JP7133544B2 (en) * | 2016-05-01 | 2022-09-08 | ユーシービー バイオファルマ エスアールエル | Affinity-engineered serum protein carrier binding domains |
| GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| PT3583125T (en) * | 2017-02-16 | 2025-04-04 | Sonnet Biotherapeutics Inc | Albumin binding domain fusion proteins |
| JP7130678B2 (en) | 2017-06-05 | 2022-09-05 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | Novel anti-HSA antibody |
| WO2018224439A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| GB201711481D0 (en) | 2017-07-17 | 2017-08-30 | Ucb Biopharma Sprl | Protein purification |
| KR102204315B1 (en) * | 2018-11-16 | 2021-01-18 | 한국세라믹기술원 | Affibody specific to human serum albumin and its use |
| US12296285B2 (en) | 2019-08-02 | 2025-05-13 | UCB Biopharma SRL | Methods for purifying antibodies |
| CN112409480B (en) * | 2019-08-20 | 2024-08-27 | 四川科伦博泰生物医药股份有限公司 | Serum albumin binding protein and its use |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| CA3175034A1 (en) | 2020-03-27 | 2021-09-30 | UCB Biopharma SRL | Autonomous knob domain peptides |
| KR102367488B1 (en) * | 2020-06-29 | 2022-02-25 | 주식회사 프로테인웍스 | A analysis method of single chain antibody fragment(scFv)-albumin drug conjugate |
| JP2023547795A (en) | 2020-10-15 | 2023-11-14 | ユーシービー バイオファルマ エスアールエル | Binding molecules that multimerize CD45 |
| KR20230118128A (en) | 2020-12-07 | 2023-08-10 | 유씨비 바이오파마 에스알엘 | Antibodies to Interleukin-22 |
| EP4255926A1 (en) | 2020-12-07 | 2023-10-11 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| CN115181751A (en) * | 2021-04-02 | 2022-10-14 | 苏州博腾生物制药有限公司 | Chimeric antigen receptors targeting albumin and methods of use thereof |
| JP2024516305A (en) | 2021-05-03 | 2024-04-12 | ユーシービー バイオファルマ エスアールエル | antibody |
| CN117545504A (en) * | 2021-06-07 | 2024-02-09 | 上海济煜医药科技有限公司 | Antigen binding proteins against human serum albumin |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| WO2023242251A1 (en) | 2022-06-15 | 2023-12-21 | UCB Biopharma SRL | Follistatin-fc fusion proteins |
| CN119654337A (en) | 2022-06-15 | 2025-03-18 | Ucb生物制药有限责任公司 | Fusion proteins for preventing, treating or ameliorating kidney diseases |
| GB202318820D0 (en) | 2023-12-08 | 2024-01-24 | UCB Biopharma SRL | Antibodies |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
| WO2025238133A1 (en) | 2024-05-17 | 2025-11-20 | UCB Biopharma SRL | Multispecific antibody with binding specificity for il-11 and il-17 |
| WO2025238135A2 (en) | 2024-05-17 | 2025-11-20 | UCB Biopharma SRL | Antibody with binding specificity for il-11 |
| WO2025248017A1 (en) | 2024-05-31 | 2025-12-04 | UCB Biopharma SRL | Method of purifying recombinant proteins |
| KR20250175017A (en) | 2024-06-05 | 2025-12-16 | 주식회사 엔바이오스 | Antibody specifically binding to HSA and use thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP1541682A3 (en) | 1988-09-02 | 2005-07-06 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A0 (en) | 1988-11-11 | 1990-07-10 | Medical Res Council | LIGANDER MED EN ENDA SEKTION, RECEPTORER INNEHAOLLANDE NAEMNDA LIGANDER, FOERFARANDEN FOER DERAS FRAMSTAELLNING SAMT ANVAENDNING AV LIGANDERNA OCH RECEPTORERNA. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE509359C2 (en) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Use of stabilized protein or peptide conjugates for the preparation of a drug |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| ES2087997T3 (en) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
| ATE414768T1 (en) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | LIBRARIES OF HETERODIMER RECEPTORS USING PHAGEMIDS |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| ATE463573T1 (en) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP1498427B1 (en) | 1992-08-21 | 2009-12-16 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DE69531148T2 (en) | 1994-01-31 | 2004-04-29 | Trustees Of Boston University, Boston | LIBRARIES MADE OF POLYCLONAL ANTIBODIES |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| DE19653722C2 (en) | 1996-12-10 | 2000-06-29 | Brose Fahrzeugteile | Adjustment device acting on both sides |
| IL131406A0 (en) | 1997-02-21 | 2001-01-28 | Genentech Inc | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies |
| GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| DK1049787T3 (en) | 1998-01-23 | 2005-04-04 | Vlaams Interuniv Inst Biotech | Antibody derivatives with multiple uses |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| ES2270893T3 (en) | 1999-12-24 | 2007-04-16 | Genentech, Inc. | PROCEDURE AND COMPOSITIONS TO EXTEND THE AVERAGE LIFE OF BIOACTIVE COMPOUNDS. |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| CA2490009A1 (en) | 2002-06-21 | 2003-12-31 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
| EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| JP4603894B2 (en) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | Assays to identify antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AU2004253738A1 (en) | 2003-07-01 | 2005-01-13 | Ucb Pharma S.A. | Modified antibody Fab fragments |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| TW200607523A (en) | 2004-06-01 | 2006-03-01 | Domantis Ltd | Drug compositions, fusions and conjugates |
| WO2006059105A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Non-cytotoxic Protein Conjugates |
| GB0506912D0 (en) | 2005-04-05 | 2005-05-11 | Celltech R&D Ltd | Biological products |
| JP5592792B2 (en) * | 2007-09-26 | 2014-09-17 | ユセベ ファルマ ソシエテ アノニム | Bispecific antibody fusions |
| LT2334705T (en) * | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | Biological products |
| EP2398498B1 (en) | 2009-02-17 | 2018-09-05 | UCB Biopharma SPRL | Antibody molecules having specificity for human ox40 |
| CN102574914A (en) | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | Improved Antiserum Albumin Binding Single Variable Domain |
| ES2667258T3 (en) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Multivalent antibodies |
| GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
-
2012
- 2012-11-09 SI SI201231119T patent/SI2776466T1/en unknown
- 2012-11-09 US US14/356,181 patent/US9803004B2/en active Active
- 2012-11-09 CN CN201280055064.0A patent/CN103946237B/en active Active
- 2012-11-09 IN IN3451DEN2014 patent/IN2014DN03451A/en unknown
- 2012-11-09 ES ES12801467.7T patent/ES2649098T3/en active Active
- 2012-11-09 EP EP12801467.7A patent/EP2776466B1/en active Active
- 2012-11-09 MX MX2014005546A patent/MX351502B/en active IP Right Grant
- 2012-11-09 HU HUE12801467A patent/HUE037142T2/en unknown
- 2012-11-09 EA EA201400568A patent/EA033766B1/en not_active IP Right Cessation
- 2012-11-09 JP JP2014540494A patent/JP6411214B2/en active Active
- 2012-11-09 WO PCT/EP2012/072335 patent/WO2013068571A1/en not_active Ceased
- 2012-11-09 SG SG11201401649VA patent/SG11201401649VA/en unknown
- 2012-11-09 PL PL12801467T patent/PL2776466T3/en unknown
- 2012-11-09 AU AU2012335496A patent/AU2012335496B2/en active Active
- 2012-11-09 PT PT128014677T patent/PT2776466T/en unknown
- 2012-11-09 HR HRP20171608TT patent/HRP20171608T1/en unknown
- 2012-11-09 BR BR112014011304-1A patent/BR112014011304B1/en active IP Right Grant
- 2012-11-09 LT LTEP12801467.7T patent/LT2776466T/en unknown
- 2012-11-09 CA CA2856216A patent/CA2856216C/en active Active
- 2012-11-09 DK DK12801467.7T patent/DK2776466T3/en active
- 2012-11-09 KR KR1020147015678A patent/KR102048382B1/en active Active
-
2013
- 2013-04-12 NO NO13716781A patent/NO2839445T3/no unknown
-
2014
- 2014-04-24 IL IL23222614A patent/IL232226B/en active IP Right Grant
-
2017
- 2017-10-27 US US15/795,874 patent/US10023631B2/en active Active
- 2017-11-22 CY CY20171101222T patent/CY1119647T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN03451A (en) | ||
| PH12014502527A1 (en) | St2 antigen binding proteins | |
| JOP20190017B1 (en) | Human cgrp receptor binding antibodies | |
| MX2018007630A (en) | Antibodies to matrix metalloproteinase 9. | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| EA201491494A1 (en) | NACELIVANIE NA GLIKANY HONDROITINSULFATY | |
| EP4282881A3 (en) | Antibodies against csf-1r | |
| NZ602220A (en) | Antibodies with ph dependent antigen binding | |
| IN2014CN03936A (en) | ||
| WO2012058308A3 (en) | Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid | |
| PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| AU2011353197A8 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding MHC-MAGE complex that induces apoptosis | |
| MX2015000754A (en) | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof. | |
| IN2014MN01868A (en) | ||
| WO2012122125A3 (en) | Compositions and methods targeting force generation in kinesin |